Liquid biopsy is a minimally invasive technique for detecting circulating tumor DNA (ctDNA) or RNA (ctRNA) in blood samples. It enables the early identification of cancer by analyzing small fragments of genetic material shed from tumors into the bloodstream.
Addresses the limitations of traditional biopsy methods by providing a non-invasive alternative that can be repeated over time, reducing patient discomfort and invasiveness.
The process involves drawing a patient's blood sample, which is then processed to isolate and sequence ctDNA or ctRNA. Bioinformatics tools are used to analyze these sequences for mutations indicative of cancer. This allows for both early detection and continuous monitoring of disease progression or treatment efficacy.
Involves the development of advanced sequencing technologies, sample preparation kits, and bioinformatics software. The manufacturing process requires precise handling to ensure the integrity of genetic material during extraction and analysis.
The build process includes steps such as blood collection, plasma isolation, ctDNA/ctRNA extraction, library preparation for sequencing, and data analysis using sophisticated algorithms.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.